Global General Anesthesia Drug Market Overview:
According to SPER Market Research, the Global General Anesthesia Drug Market is estimated to reach USD 3.09 billion by 2032 with a CAGR of 3.7%.
The purpose of a general anesthetic is to induce and maintain an unconscious state without any pain perception. Essentially, it is an intentionally inflicted state of unconsciousness coupled with a partial or whole absence of protective reflexes.
Impact of COVID-19 on the Global General Anesthesia Drug Market
In 2020, fewer surgeries were performed or postponed because of a modest decline in demand for anesthetic medicines brought on by the pandemic crisis. Approximately 28.4 million elective procedures are expected to be postponed or canceled worldwide, according to a study published in the British Journal of Surgery in May 2020. This estimate was based on a 12-week period during which COVID-19 caused the most severe disruption to hospital services. But as things get back to normal, all of the delayed elective procedures are now being finished, which leads to a rise in the number of anesthetic drugs taken.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Drug Type, By Route of Administration, By Surgery Type, By End User. |
| Geographies covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | Abbott Laboratories, Abbvie, Akorn, Apotex, Astra Zeneca Plc, Baxter International Inc., Bayer AG, F. Hoffmann- La Roche, Fresenius Se & Co KgaA, Gilead Science Inc., Galxo SmithKline Plc, Heritage Pharmaceutical Inc., Hikma Pharmaceuticals Plc, Merck & Co Inc., Novarits AG, Par Pharmaceuticals, Pfizer Inc., Piramal Enterprises Ltd., Sanofi, Teva Pharmaceuticals.
|
Global General Anesthesia Drug Market Segmentation:
By Drug Type: Based on the Drug Type, Global General Anesthesia Drug Market is segmented as: Propofol, Sevoflurane, Desflurane, Others.
By Route of Administartion: Based on the Route of Administration, Global General Anesthesia Drug Market is segmented as: Inhalation, Intravenous.
By Surgery Type: Based on the Surgery Type, Global General Anesthesia Drug Market is segmented as: Knee and Hip Replacements, Heart Surgery, Cancer Surgery, General Surgery.
By End User: Based on the End User, Global General Anesthesia Drug Market is segmented as: Hospitals, Ambulatory Surgical Centres.
By Region: North America owns the prime share of this market; the major factors of the market's growth in the region are the increasing incidence of chronic illnesses, the growing amount of medicine prescriptions brought on by the region's rapidly aging population, and the expansion of key market participants in the area.
1.2. Market segment analysis
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.2. COVID-19 Impacts of the Global General Anesthesia Drugs Market
5. Market variables and outlook
5.2.1 Political landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
6. Global General Anesthesia Drug Market, By Drug Type, 2019-2032 (USD Million)
7. Global General Anesthesia Drug Market, By Route of Administration, 2019-2032 (USD Million)
8. Global General Anesthesia Drug Market, By Surgery Type, 2019-2032 (USD Million)
8.1 Knee and Hip replacements
9. Global General Anesthesia Drug Market, By End User, 2019-2032 (USD Million)
9.2 Ambulatory Surgical centers
10 Global General Anesthesia Drug Market, By Region, 2019-2032 (USD Millions)
10.3.6 Rest of Asia-Pacific
10.4.3 Rest of South America
10.5 Middle East & Africa
10.5.1 Kingdom of Saudi Arabia
10.5.2 United Arab Emirates
10.5.3 Rest of Middle East & Africa
11. Company Profiles
11.1 Abbott Laboratories
11.1.4 Recent developments
11.2.4 Recent developments
11.3.4 Recent developments
11.4.4 Recent developments
11.5.4 Recent developments
11.6 Baxter International Inc.
11.6.4 Recent developments
11.7.4 Recent developments
11.8 F.Hoffmann- La Roche
11.8.4 Recent developments
11.9 Fresenius Se & Co KGaA
11.9.4 Recent developments
11.10 Gileda Science Inc.
11.10.2 Financial outlook
11.10.4 Recent developments
11.11 GalxoSmithKline Plc
11.11.2 Financial outlook
11.11.4 Recent developments
11.12 Heritage Pharmaceuticals Inc.
11.12.2 Financial outlook
11.12.4 Recent developments
11.13 Hikma Pharmaceuticals Plc
11.13.2 Financial outlook
11.13.4 Recent developments
11.14.2 Financial outlook
11.14.4 Recent developments
11.15.2 Financial outlook
11.15.4 Recent developments
11.16 Par Pharmaceuticals
11.16.2 Financial outlook
11.16.4 Recent developments
11.17.2 Financial outlook
11.17.4 Recent developments
11.18 Piramal Enterprises Ltd.
11.18.2 Financial outlook
11.18.4 Recent developments
11.19.2 Financial outlook
11.19.4 Recent developments
11.20 Teva Pharmaceuticals
11.20.2 Financial outlook
11.20.4 Recent developments
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
